Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons - Possible involvement of endogenous kynurenic acid

Synapse

Volumn 59, Issue 5, 2006, Pages 290-298

  Schwieler, Lilly ^a   Erhardt, Sophie ^a   Nilsson, Linda ^a   Linderholm, Klas ^a   Engberg, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

D cycloserine; Glutamate; Indomethacin; L 701,324; Parecoxib; Schizophrenia

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; APOMORPHINE; CHLORAL HYDRATE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSERINE; GLUTAMATE RECEPTOR ANTAGONIST; INDOMETACIN; KYNURENIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PARECOXIB; PARTIAL AGONIST;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPHYSIOLOGY; HISTOGRAM; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NERVE CELL MEMBRANE POTENTIAL; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE; SPIKE; STATISTICAL ANALYSIS; VENTRAL TEGMENTUM;

ACTION POTENTIALS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DRUG INTERACTIONS; ELECTROCHEMISTRY; ENZYME INHIBITORS; INDOMETHACIN; ISOXAZOLES; KYNURENIC ACID; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; VENTRAL TEGMENTAL AREA;

EID: 33144486462     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20241     Document Type: Article

References (56)

1. Birch PJ, Grossman CJ, Hayes AG. 1988. Kynurenic acid antagonizes responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154:85-87.
2. Carlsson A. 2001. A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture. Biosci Rep 21:691-710.
3. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. 2001. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 41:237-260.
4. Clunie M, Crone LA, Klassen L, Yip R. 2003. Psychiatric side effects of indomethacin in parturients. Can J Anest 50:586-588.
5. Di Chiara G, Porceddu ML, Morelli M, Mulas ML, Gessa GL. 1979. Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons. N-S Arch Pharmacol 2:153-159.
6. Erhardt S, Engberg G. 2002. Increased phasic activity of dopaminergic neurons in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 175:45-53.
7. Erhardt S, Öberg H, Mathé JM, Engberg G. 2001a. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20:353-362.
8. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. 2001b. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313:96-98.
9. B-receptors modulate the firing pattern of dopamine neurons in the ventral tegmental area. N-S Arch Pharmacol 365:173-180.
10. Erhardt S, Schwieler L, Engberg G. 2003. Kynurenic acid and schizophrenia. Adv Exp Med Biol 527:155-165.
11. Fibiger HC, Phillips AG. 1988. Mesocorticolimbic dopamine systems and reward. Ann NY Acad Sci 537:206-215.
12. Franzone JS, Cravanzola C, Reboani MC. 1980. Influence of non-steroidal anti-inflammatory compounds on the hepatic tryptophan pyrrolase activity in hypo- and hyperthyroid rats. Arch Int Pharmacodyn Ther 245:156-165.
13. French ED. 1994. Phencyclidine and the midbrain dopamine system: electrophysiology and behavior. Neurotoxicol Teratol 16:355-362.
14. French ED, Mura A, Wang T. 1993. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 13:108-116.
15. Gonon FG. 1988. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24:19-28.
16. Grace AA, Bunney BS. 1984a. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4:2866-2876.
17. Grace AA, Bunney BS. 1984b. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890.
18. Grimwood S, Kulagowski JJ, Mawer IM, Rowley M, Leeson PD, Foster AC. 1995. Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists. Eur J Pharmacol 290:221-226.
19. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ. 2001. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842-853.
20. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. 2001. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473.
21. Hoppman RA, Peden JG, Ober SK. 1991. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Int Med 151:1309-1313.
22. Jiang HK, Chang DM. 1999. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 18:339-345.
23. Kessler M, Terramani T, Lynch G, Baudry MJ. 1989. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319-1328.
24. Kiss C, Ceresoli-Borroni G, Guidetti P, Zielke CL, Zielke HR, Schwarcz R. 2003. Kynurenate production by cultured human astrocytes. J Neural Transm 110:1-14.
25. LeMoal M, Simon H. 1991. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 71:155-234.
26. McCormack K. 1994. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 47:28-45.
27. Melis M, Diana M, Gessa GL. 2000. Cyclo-oxygenase-inhibitors increase morphine effects on mesolimbic dopamine neurons. Eur J Pharmacol 387:R1-R3.
28. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. 2004. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15:618-629.
29. Müller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ. 2002. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatr 159:1029-1034.
30. Naidu PS, Kulkarni SK. 2002. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Progr Neuropsychopharmacol Biol Psychiatr 26:819-822.
31. Newman EA. 2003. New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci 10:536-542.
32. Nilsson LK, Linderholm KL, Engberg G, Paulson L, Blennow K, Lindström LH, Nordin C, Karanti A, Erhardt S. 2005. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schiz Res 80:315-322.
33. Nissbrandt H, Elverfors A, Engberg G. 1994. Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. Synapse 17:217-224.
34. Ono N, Abiru T, Sugiyama K, Kamiya H. 1992. Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostaglandins Leukot Essent Fatty Acids 46:59-63.
35. Overton P, Clark D. 1992. Iontophoretically administered drugs acting at the N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse 10:131-140.
36. Overton PG, Clark D. 1997. Burst firing in midbrain dopaminergic neurons. Brain Res Rev 25:312-334.
37. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM. 1997. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283:1264-1275.
38. Paxinos G, Watson C, eds. 1998. The rat brain in stereotaxic coordinates, 4th ed. New York: Academic Press.
39. Ross BM, Brooks RJ, Lee M, Kalasinsky KS, Vorce SP, Seeman M, Fletcher PJ, Turenne SD. 2002. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol 23:141-151.
40. Schilström B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH. 2003. Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol 6:1-11.
41. Schultz W. 1998. Predictive reward signal of dopamine neurons. J Neurophysiol 80:1-27.
42. Schultz W, Apicella P, Ljungberg T. 1993. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J Neurosci 13:900-913.
43. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. 2001. Increased cortical kynurenate content in schizophrenia. Biol Psychiatr 50:521-530.
44. Schwieler L, Engberg G, Erhardt S. 2004. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 52:114-122.
45. Schwieler L, Erhardt S, Erhardt C, Engberg G. 2005. Prostaglandin- mediated control of rat brain kynurenic acid synthesis-opposite roles by COX-1 and COX-2 isoforms. J Neural Transm 12:863-872.
46. Stanford IM, Lacey MG. 1996. Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J Neurosci 23:7566-7573.
47. Steffensen SC, Svingos AL, Pickel VM, Henriksen SJ. 1998. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J Neurosci 19:8003-8015.
48. Stone TW. 1993. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309-379.
49. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K. 2000. N-[[(5-methyl-3-phenylisoxazol-4- yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 43:1661-1663.
50. Tharumaratnam D, Bashford S, Khan SA. 2000. Indomethacin induced psychosis. Postgrad Med J 76:736-737.
51. Wang RY. 1981. Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3:123-140.
52. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. 1999. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Nat Acad Sci USA 96:7563-7568.
53. Werner G, Mountcastle VB. 1963. The variability of central neural activity in a sensory system and its implification for the central reflection of sensory events. J Neurophysiol 26:958-977.
54. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. 2003. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann NY Acad Sci 1003:53-74.
55. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. 1993. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11:371-386.
56. Zhang J, Chiodo LA, Freeman AS. 1992. Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res 590:153-163.